IL1B and lung carcinoma: Inhibition of IL-1B signalling has been shown to have an anti-tumour effect in the CANTOS trial, in that patients with previous myocardial infarction and high C-reactive protein levels assigned to receive Canakinumab, displayed reduced lung cancer mortality31,32.